Literature DB >> 31668804

Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform.

Eytan Herzig1, Kaman Chan Kim2, Thomas A Packard1, Noam Vardi3, Roland Schwarzer1, Andrea Gramatica1, Steven G Deeks4, Steven R Williams2, Kyle Landgraf2, Nigel Killeen2, David W Martin2, Leor S Weinberger5, Warner C Greene6.   

Abstract

Current approaches to reducing the latent HIV reservoir entail first reactivating virus-containing cells to become visible to the immune system. A critical second step is killing these cells to reduce reservoir size. Endogenous cytotoxic T-lymphocytes (CTLs) may not be adequate because of cellular exhaustion and the evolution of CTL-resistant viruses. We have designed a universal CAR-T cell platform based on CTLs engineered to bind a variety of broadly neutralizing anti-HIV antibodies. We show that this platform, convertibleCAR-T cells, effectively kills HIV-infected, but not uninfected, CD4 T cells from blood, tonsil, or spleen and only when armed with anti-HIV antibodies. convertibleCAR-T cells also kill within 48 h more than half of the inducible reservoir found in blood of HIV-infected individuals on antiretroviral therapy. The modularity of convertibleCAR-T cell system, which allows multiplexing with several anti-HIV antibodies yielding greater breadth and control, makes it a promising tool for attacking the latent HIV reservoir.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CAR-T; HIV latency; MicAbody; T cell therapy; bNAb; broadly neutralizing HIV antibodies; convertibleCAR-T; reduce-and-control; reservoir; shock-and-kill

Mesh:

Substances:

Year:  2019        PMID: 31668804      PMCID: PMC6922308          DOI: 10.1016/j.cell.2019.10.002

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  122 in total

1.  BET bromodomain inhibition as a novel strategy for reactivation of HIV-1.

Authors:  Camellia Banerjee; Nancie Archin; Daniel Michaels; Anna C Belkina; Gerald V Denis; James Bradner; Paola Sebastiani; David M Margolis; Monty Montano
Journal:  J Leukoc Biol       Date:  2012-07-16       Impact factor: 4.962

2.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

Authors:  Elena Sotillo; David M Barrett; Kathryn L Black; Asen Bagashev; Derek Oldridge; Glendon Wu; Robyn Sussman; Claudia Lanauze; Marco Ruella; Matthew R Gazzara; Nicole M Martinez; Colleen T Harrington; Elaine Y Chung; Jessica Perazzelli; Ted J Hofmann; Shannon L Maude; Pichai Raman; Alejandro Barrera; Saar Gill; Simon F Lacey; Jan J Melenhorst; David Allman; Elad Jacoby; Terry Fry; Crystal Mackall; Yoseph Barash; Kristen W Lynch; John M Maris; Stephan A Grupp; Andrei Thomas-Tikhonenko
Journal:  Cancer Discov       Date:  2015-10-29       Impact factor: 39.397

3.  Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue.

Authors:  Gilad Doitsh; Marielle Cavrois; Kara G Lassen; Orlando Zepeda; Zhiyuan Yang; Mario L Santiago; Andrew M Hebbeler; Warner C Greene
Journal:  Cell       Date:  2010-11-24       Impact factor: 41.582

4.  HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.

Authors:  Julia A Sung; Shabnum Patel; Matthew L Clohosey; Lauren Roesch; Tamara Tripic; JoAnn D Kuruc; Nancie Archin; Patrick J Hanley; C Russell Cruz; Nilu Goonetilleke; Joseph J Eron; Clio M Rooney; Cynthia L Gay; Catherine M Bollard; David M Margolis
Journal:  Mol Ther       Date:  2018-09-21       Impact factor: 11.454

Review 5.  Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic.

Authors:  Marina Caskey; Florian Klein; Michel C Nussenzweig
Journal:  Nat Med       Date:  2019-04-01       Impact factor: 53.440

6.  Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.

Authors:  Marina Caskey; Till Schoofs; Henning Gruell; Allison Settler; Theodora Karagounis; Edward F Kreider; Ben Murrell; Nico Pfeifer; Lilian Nogueira; Thiago Y Oliveira; Gerald H Learn; Yehuda Z Cohen; Clara Lehmann; Daniel Gillor; Irina Shimeliovich; Cecilia Unson-O'Brien; Daniela Weiland; Alexander Robles; Tim Kümmerle; Christoph Wyen; Rebeka Levin; Maggi Witmer-Pack; Kemal Eren; Caroline Ignacio; Szilard Kiss; Anthony P West; Hugo Mouquet; Barry S Zingman; Roy M Gulick; Tibor Keler; Pamela J Bjorkman; Michael S Seaman; Beatrice H Hahn; Gerd Fätkenheuer; Sarah J Schlesinger; Michel C Nussenzweig; Florian Klein
Journal:  Nat Med       Date:  2017-01-16       Impact factor: 53.440

7.  Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015.

Authors: 
Journal:  Lancet HIV       Date:  2016-07-19       Impact factor: 12.767

8.  bNAber: database of broadly neutralizing HIV antibodies.

Authors:  Alexey M Eroshkin; Andrew LeBlanc; Dana Weekes; Kai Post; Zhanwen Li; Akhil Rajput; Sal T Butera; Dennis R Burton; Adam Godzik
Journal:  Nucleic Acids Res       Date:  2013-11-07       Impact factor: 16.971

9.  The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication.

Authors:  Victoria E Walker-Sperling; Christopher W Pohlmeyer; Patrick M Tarwater; Joel N Blankson
Journal:  EBioMedicine       Date:  2016-04-18       Impact factor: 8.143

Review 10.  Engineering and Design of Chimeric Antigen Receptors.

Authors:  Sonia Guedan; Hugo Calderon; Avery D Posey; Marcela V Maus
Journal:  Mol Ther Methods Clin Dev       Date:  2018-12-31       Impact factor: 6.698

View more
  40 in total

Review 1.  Pediatric HIV: the Potential of Immune Therapeutics to Achieve Viral Remission and Functional Cure.

Authors:  Stella J Berendam; Ashley N Nelson; Ria Goswami; Deborah Persaud; Nancy L Haigwood; Ann Chahroudi; Genevieve G Fouda; Sallie R Permar
Journal:  Curr HIV/AIDS Rep       Date:  2020-06       Impact factor: 5.071

Review 2.  Next-generation stem cells - ushering in a new era of cell-based therapies.

Authors:  Erin A Kimbrel; Robert Lanza
Journal:  Nat Rev Drug Discov       Date:  2020-04-06       Impact factor: 84.694

3.  A Universal CAR-NK Cell Targeting Various Epitopes of HIV-1 gp160.

Authors:  Rebecca M Lim; Liang Rong; Anjie Zhen; Jianming Xie
Journal:  ACS Chem Biol       Date:  2020-07-28       Impact factor: 5.100

4.  HIV enters deep sleep in people who naturally control the virus.

Authors:  Nicolas Chomont
Journal:  Nature       Date:  2020-09       Impact factor: 49.962

Review 5.  The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies.

Authors:  Lillian B Cohn; Nicolas Chomont; Steven G Deeks
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

6.  Human Vaccines & Immunotherapeutics: news.

Authors: 
Journal:  Hum Vaccin Immunother       Date:  2019       Impact factor: 3.452

7.  P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas.

Authors:  Liat Rousso-Noori; Ignacio Mastandrea; Shauli Talmor; Tova Waks; Anat Globerson Levin; Maarja Haugas; Tambet Teesalu; Luis Alvarez-Vallina; Zelig Eshhar; Dinorah Friedmann-Morvinski
Journal:  Nat Commun       Date:  2021-06-14       Impact factor: 14.919

Review 8.  The state of latency in microbial pathogenesis.

Authors:  Liise-Anne Pirofski; Arturo Casadevall
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

Review 9.  Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy.

Authors:  Yuqi Zhou; Colby R Maldini; Julie Jadlowsky; James L Riley
Journal:  J Infect Dis       Date:  2021-02-15       Impact factor: 5.226

Review 10.  Challenges and Promise of Human Immunodeficiency Virus Remission.

Authors:  Yijia Li; Abbas Mohammadi; Jonathan Z Li
Journal:  J Infect Dis       Date:  2021-02-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.